242 related articles for article (PubMed ID: 15735013)
1. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
Liu S; Shen T; Huynh L; Klisovic MI; Rush LJ; Ford JL; Yu J; Becknell B; Li Y; Liu C; Vukosavljevic T; Whitman SP; Chang KS; Byrd JC; Perrotti D; Plass C; Marcucci G
Cancer Res; 2005 Feb; 65(4):1277-84. PubMed ID: 15735013
[TBL] [Abstract][Full Text] [Related]
2. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
[TBL] [Abstract][Full Text] [Related]
3. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
[TBL] [Abstract][Full Text] [Related]
4. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
5. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
6. Role of RUNX family members in transcriptional repression and gene silencing.
Durst KL; Hiebert SW
Oncogene; 2004 May; 23(24):4220-4. PubMed ID: 15156176
[TBL] [Abstract][Full Text] [Related]
7. Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3.
Iwatsuki K; Tanaka K; Kaneko T; Kazama R; Okamoto S; Nakayama Y; Ito Y; Satake M; Takahashi S; Miyajima A; Watanabe T; Hara T
Oncogene; 2005 Feb; 24(7):1129-37. PubMed ID: 15592512
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.
Matsushita H; Kizaki M; Kobayashi H; Muto A; Ikeda Y
Br J Cancer; 1999 Mar; 79(9-10):1325-31. PubMed ID: 10188872
[TBL] [Abstract][Full Text] [Related]
9. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
10. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts.
Dunne J; Cullmann C; Ritter M; Soria NM; Drescher B; Debernardi S; Skoulakis S; Hartmann O; Krause M; Krauter J; Neubauer A; Young BD; Heidenreich O
Oncogene; 2006 Oct; 25(45):6067-78. PubMed ID: 16652140
[TBL] [Abstract][Full Text] [Related]
11. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
12. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.
Duque-Afonso J; Yalcin A; Berg T; Abdelkarim M; Heidenreich O; Lübbert M
Oncogene; 2011 Jul; 30(27):3062-72. PubMed ID: 21577204
[TBL] [Abstract][Full Text] [Related]
13. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
14. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
15. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
16. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
17. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
18. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
19. Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway.
McCabe MT; Davis JN; Day ML
Cancer Res; 2005 May; 65(9):3624-32. PubMed ID: 15867357
[TBL] [Abstract][Full Text] [Related]
20. The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages.
Himes SR; Cronau S; Mulford C; Hume DA
Oncogene; 2005 Aug; 24(34):5278-86. PubMed ID: 16007221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]